Fate Therapeutics (FATE) Stock Price, Quote & News

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 875 1800

Website: www.fatetherapeutics.com

Address:

12278 Scripps Summit Drive, San Diego, United States

Randy2979 Apr. 5 at 1:19 AM

$FATE New 18th location

1 · Reply

focafoca99 Apr. 3 at 8:27 PM

$FATE granted inducement RSUs covering 7,260 shares to one new employee.

0 · Reply

OfficialStocktwitsUser Apr. 3 at 3:05 AM

$FATE RSI: 54.55, MACD: -0.0222 Vol: 0.08, MA20: 1.19, MA50: 1.26 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Jake140 Apr. 2 at 10:45 AM

$FATE Hey Gang...still very bullish here. Been a rough few weeks in the market as we all know, but I remain invested and firmly believe in this company's potential.

0 · Reply

cta7978 Mar. 31 at 5:35 PM

$FATE

0 · Reply

None_ Mar. 31 at 9:43 AM

$FATE At ASGCT '25, Fate presented preclinical data on targeting uPAR with a multiplexed-engineered CAR-T to reverse age- and insult-related fibrotic disease. Now this has just been published https://medicalxpress.com/news/2026-03-upar-car-cells-shrank-solid.html

0 · Reply

Rocketman808 Mar. 27 at 9:08 PM

$FATE April should be boring, news likely in May going into EULAR. i guess next ER around then too

0 · Reply

radonco Mar. 27 at 3:01 AM

$FATE vanguard group filing today - sold out of position (8.7M shares)

2 · Reply

moneytome Mar. 26 at 2:09 PM

$FATE $CRDL $NKLR $GOGO look for continuation

0 · Reply

radonco Mar. 25 at 5:27 PM

$FATE looks like two autoimmune deals today…Gilead buying Ouro for T cell engager for $1.6B and Sanofi licensing deal with Kali therapeutic for trispecific T cell engager (CD19/BCMA/CD3) with $180M upfront and $1B in milestones. I’ve said it before…lots of competition in autoimmune space to deplete B cells, treat B cell lymphoma, etc. I hope Fate brings results to compete with all these companies and their different approaches. I don’t like how saturated the field is becoming however.

1 · Reply

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2026, 4:05 PM EST - 4 weeks ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 4:05 PM EST - 4 weeks ago

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Feb 16, 2026, 1:00 PM EST - 7 weeks ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

IPSC

Nov 25, 2025, 8:00 AM EST - 4 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 5 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Oct 26, 2025, 11:30 AM EDT - 5 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Aug 12, 2025, 4:01 PM EDT - 8 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jun 11, 2025, 9:00 AM EDT - 10 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 11 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 11 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 13, 2025, 4:01 PM EDT - 11 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 9:25 AM EDT - 1 year ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Mar 5, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

May 29, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 9, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 2 years ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Mar 19, 2024, 8:44 AM EDT - 2 years ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

May 31, 2023, 8:00 AM EDT - 3 years ago

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 3, 2023, 4:01 PM EDT - 3 years ago

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Apr 24, 2023, 8:00 AM EDT - 3 years ago

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

Mar 21, 2023, 5:45 PM EDT - 3 years ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Feb 28, 2023, 4:01 PM EST - 3 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Feb 13, 2023, 8:00 AM EST - 3 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results

Randy2979 Apr. 5 at 1:19 AM

$FATE New 18th location

1 · Reply

focafoca99 Apr. 3 at 8:27 PM

$FATE granted inducement RSUs covering 7,260 shares to one new employee.

0 · Reply

OfficialStocktwitsUser Apr. 3 at 3:05 AM

0 · Reply

Jake140 Apr. 2 at 10:45 AM

$FATE Hey Gang...still very bullish here. Been a rough few weeks in the market as we all know, but I remain invested and firmly believe in this company's potential.

0 · Reply

cta7978 Mar. 31 at 5:35 PM

$FATE

0 · Reply

None_ Mar. 31 at 9:43 AM

0 · Reply

Rocketman808 Mar. 27 at 9:08 PM

$FATE April should be boring, news likely in May going into EULAR. i guess next ER around then too

0 · Reply

radonco Mar. 27 at 3:01 AM

$FATE vanguard group filing today - sold out of position (8.7M shares)

2 · Reply

moneytome Mar. 26 at 2:09 PM

$FATE $CRDL $NKLR $GOGO look for continuation

0 · Reply

radonco Mar. 25 at 5:27 PM

1 · Reply

radonco Mar. 25 at 5:04 PM

$FATE cause you gotta have FATE

0 · Reply

moneytome Mar. 25 at 3:53 PM

$FATE may repeat the history of running to around 1.7 and above

0 · Reply

Nik7777 Mar. 23 at 4:36 PM

$FATE

0 · Reply

Goodstockday Mar. 23 at 4:23 PM

$FATE The volatility in this stock is crazy. That volatility brings out the day traders and it only gets worse. You add in the Trump/Iran stuff and you throw more fuel on the volatility fire. This should be a $1.75 stock right now with minimal fluctuations until the next data news.

2 · Reply

rlombard3 Mar. 23 at 1:14 PM

$FATE

0 · Reply

Rocketman808 Mar. 23 at 11:25 AM

$FATE temporary macro reprieve via TACO tweet. show me some bigger volume today than Friday!

0 · Reply

Rocketman808 Mar. 20 at 6:00 PM

$FATE watching volume here. like the loading going on down here. massive lots just went through

1 · Reply

Rocketman808 Mar. 20 at 2:28 PM

$FATE more for the next trip

0 · Reply

Nik7777 Mar. 19 at 5:14 PM

$FATE

0 · Reply

aw20 Mar. 19 at 2:35 PM

$FATE grabbed more at 1.04 👀

0 · Reply

Rocketman808 Mar. 18 at 9:05 PM

$FATE Fate Therapeutics (NASDAQ: FATE) — Off-the-Shelf CAR T as Same-Day Outpatient Therapy $XBI

1 · Reply

Rocketman808 Mar. 18 at 9:04 PM

$FATE will take the free press from Avai paid article. just hit the newswire. its never bad to be in an article titled $45B and get our same day discharge highlighted! https://stocks.apple.com/ApWsGGI3LQTi4qXegNOGs-w

0 · Reply

Market Cap	141.84M
Revenue (ttm)	6.65M
Net Income (ttm)	-136.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,049.92%
Debt to Equity Ratio	0.00

Volume	852,800
Avg Vol	1,539,150
Day's Range	N/A - N/A
Shares Out	116.26M
Stochastic %K	43%
Beta	2.23
Analysts	Sell
Price Target	$4.94